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CLINICAL THERAPEUTICS
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ABSTRACT Chagas disease reactivation in HIV-positive people is an opportunistic
infection with 79 to 100% mortality. It commonly involves the central nervous system
(CNS). Early treatment with trypanocidal drugs such as benznidazole (BNZ) is crucial
for this severe manifestation of Trypanosoma cruzi infection. However, limited BNZ
clinical pharmacology data are available, especially its concentration in the CNS. We
report a series of HIV-positive patients undergoing treatment for T. cruzi meningoencephalitis, their clinical response, and cerebrospinal ﬂuid (CSF) and plasma BNZ concentrations. Measurements were carried out using leftover samples originally
obtained for routine medical care. A high-performance liquid chromatography/tandem mass spectrometry bioanalytical method designed for BNZ plasma measurements was adapted and validated for CSF samples. Six patients were enrolled in this
study from 2015 to 2019. A total of 6 CSF and 19 plasma samples were obtained.
Only three of the CSF samples had detectable BNZ levels, all under 1 m g/ml. Fifteen
plasma samples had detectable BNZ, and 13 were above 2 m g/ml, which is the putative trypanocidal level. We observed BNZ concentrations in human CSF and plasma.
CSF BNZ concentrations were low or not measurable in all patients, suggesting that
the usual BNZ doses may be suboptimal in HIV-positive patients with T. cruzi meningoencephalitis. While drug-drug and drug-disease interactions may be in part responsible, the factors leading to low CSF BNZ levels remain to be studied in detail. These
ﬁndings highlight the potential of therapeutic drug monitoring in BNZ treatment and
suggest that the use of higher doses may be useful for Chagas disease CNS
reactivations.
KEYWORDS Chagas disease, Trypanosoma cruzi, meningoencephalitis, HIV/AIDS,

benznidazole, therapeutic drug monitoring

C

hagas disease (CD), or American trypanosomiasis, reactivation is an opportunistic
infection in HIV positive patients commonly presenting as meningoencephalitis
and/or central nervous system abscesses (called “Chagomas”) and leads to nearly 100%
mortality in untreated patients (1–4). Diagnosis of CD reactivation is based on
Trypanosoma cruzi detection in cerebrospinal ﬂuid (CSF), blood or other ﬂuids or in tissues, usually brain biopsy smears (as amastigote nests with acute inﬂammatory inﬁltrates) (5, 6). Immediate treatment with trypanocidal agents such as benznidazole
(BNZ) or nifurtimox is essential to reduce morbidity and mortality. BNZ is the most commonly used trypanocidal agent and is usually chosen as ﬁrst-line treatment. However,
understanding of BNZ pharmacokinetics (PK) and pharmacodynamics is quite limited,
particularly for a drug that was developed almost 50 years ago (7–13). Information on
BNZ absorption, metabolism, distribution, and excretion is scarce, preventing accurate
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prediction of drug-drug and drug-disease interactions. To date, there is virtually no
published information on plasma and CSF BNZ concentrations, their pharmacokinetics
in HIV-seropositive patients, or the potential interactions between BNZ and antiretrovirals or other drugs (14, 15). Therefore, the pharmacotherapy of CD central nervous system (CNS) reactivations is commonly guided by limited empirical knowledge, and thus
the degree of uncertainty surrounding optimal BNZ pharmacotherapy for these
patients is high.
The aim of this publication is to report clinical data and BNZ measurements in CSF
and plasma from a cohort of HIV-positive patients with CD CNS reactivation treated
with BNZ.
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RESULTS
A total of 6 patients (age range, 39 to 69 years; 2 women) were included in this
cohort, all of them had a previous diagnosis of both HIV infection and positive T. cruzi
serology. All patients had CNS symptoms at presentation, and all were treated during
hospital admission for CNS CD reactivation with BNZ (5 to 8 mg/kg/day twice daily for
60 days) when possible (i.e., if patients survived to complete the full treatment). The
time between patient admission to our institution and CD treatment was ,2 days for
most patients, except for patient B, who started BNZ after 5 days, and patient E, who
started BNZ on day 10 of hospitalization. Four of the six patients died, yielding a high
mortality rate despite appropriate treatment, as has commonly been reported for such
severe conditions.
Clinical data and outcomes are presented for each patient in Table 1. All patients
had low CD41 lymphocyte counts (range, 7 to 25 cells/mm3) on admission. Only patient
F was receiving antiretroviral treatment (started 2 weeks before admission; the HIV load
was 2,240 copies/m l 2 months after admission). The remaining patients were not taking
antiretrovirals due to a history of nonadherence to follow-up as HIV-positive outpatients. All patients received multiple medications during hospital stay (Table 1). The
two female patients survived after CD reactivation with neurological improvement and
followed up as outpatients for 3 years (patient A) and 6 months (patient F). Patient A
started highly active antiretroviral therapy during hospitalization, immediately after the
improvement of neurological symptoms (i.e., after 20 days of BNZ treatment).
Neurotoxoplasmosis could not be completely ruled out in all patients, since none had
undergone brain biopsy and Toxoplasma gondii PCR was not available in our institution.
Due to the severe clinical presentations and the dire consequences of delaying treatment, all patients received empirical simultaneous treatment for CD and toxoplasmosis.
Treatment for T. gondii encephalitis was performed with either pyrimethamine plus sulfadiazine or clindamycin or with trimethoprim-sulfamethoxazole. BNZ was well tolerated in most patients. Only one patient (patient A) was switched to nifurtimox 10 mg/
kg/day after 30 days of BNZ due to severe leukopenia, with good adherence and
response to nifurtimox.
The BNZ concentrations obtained from all CSF and plasma samples are presented in
Table 2. Half of the patients CSF samples had undetectable BNZ CSF levels. Patients
who had detectable BNZ CSF levels had BNZ concentrations of ,1 m g/ml. The two survivors of this series had detectable BNZ CSF levels (patient A, 0.5 m g/ml; patient F,
0.3 m g/ml). Paired samples of CSF and plasma to calculate BNZ CSF/plasma ratio were
available for patient E (who had undetectable BNZ in plasma and CSF paired samples)
and patient F with a BNZ CSF/plasma ratio of 0.1.
Plasma BNZ was quantiﬁable in 15 of 19 samples; from these 15 samples, 13 had
BNZ concentrations above 2 m g/ml, which is the putative trypanocidal level (16). A total
of 6 plasma samples had BNZ concentrations below the trypanocidal level; 4 were
taken 12 h after BNZ administration (i.e., just before the next dose). Parasitemia, as
measured by T. cruzi PCR on peripheral venous blood, became undetectable in most of
the patients during BNZ treatment, except for one patient (patient E), who had undetectable BNZ levels in most samples and detectable T. cruzi PCR on day 13 of BNZ
treatment.
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Right-sided
hemiparesis

Altered state of
consciousness

Seizures

Altered state of
consciousness

Symptoms
Right-sided
hemiparesis
Left-sided
hemiparesis

NEG

NA

NA

NA

NEG

Blood
POS

POS

POS

POS

POS

NEG

CSF
NA

Omeprazole, pyrimethamine, clindamycin,
trimethoprim-sulfamethoxazole, leucovorin,
ﬂuconazole, tenofovir, emtricitabine, lopinavirritonavir

Omeprazole, dexamethasone, pyrimethamine,
clindamycin, ciproﬂoxacin, leucovorin, fentanyl

Omeprazole, pyrimethamine, sulfadiazine, phenytoin,
lorazepam, ﬂuconazole, prednisone

Concomitant medications
Omeprazole, dexamethasone, pyrimethamine,
clindamycin, ganciclovir, folic acid.
Ranitidine, dexamethasone, pyrimethamine,
sulfadiazine, phenytoin, metoclopramide,
amitriptyline, lorazepam.
Omeprazole, dexamethasone, trimethoprimsulfamethoxazole, amphotericin B, ibuprofen,
diphenhydramine

Clinical evolution
Good response; alive up 3 yrs after Chagas
disease reactivation
Patient died after 1 mo of BNZ treatment
prior to stereotactic brain biopsy due to
an acute abdominal complication
Died after 15 days of hospitalization with 4
conﬁrmed opportunistic CNS infections:
Cryptococcus spp. (Indian ink and
culture positive), CMV (RT-PCR positive
on CSF) and culture of M. tuberculosis
positive on CSF.
Initial improvement after T. cruzi
reactivation but died after 1 mo of
treatment due to status epilepticus,
probably caused by sequelae of brain
lesions.
Poor clinical course; admitted to intensive
care unit, requiring mechanic
ventilation complicated with ventilatoracquired pneumonia, multiorgan failure
and died after 2 wks of BNZ treatment.
Good clinical response; she recovered and
was discharged after 1 mo to continue
follow-up as an outpatient

count of CD41 cells (cells/ mm3); F, female, M, male, CNS, central nervous system, CSF, cerebrospinal ﬂuid, CMV, cytomegalovirus. NA, not available, POS, positive, NEG, negative.

50

B

Sex
F

Downloaded from http://aac.asm.org/ on February 17, 2021 by guest

March 2021 Volume 65 Issue 3 e01922-20

aCD4, absolute

Age (yr)
39

Patient ID
A

Microscopic
detection of
parasites

TABLE 1 Clinical data at admission, therapeutic data, and clinical evolutiona
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TABLE 2 BNZ concentration obtained from all CSF and plasma samplesa
Plasma BNZ data

CSF BNZ data
Plasmatic BNZ
(m g/ml)
6.5
11.9

Sampling time (h)
after last intake
0.5
4

Duration (days) of
BNZ treatment
NA
22b

CSF BNZ
(m g/ml)
NA
0.5

Sampling time (h)
after last intake
NA
7

B

3
10
10
17
17

8.8
2.3
6.2
,LOD
5.5

0.5
12
3
12
3

NA
NA
10
NA
NA

NA
NA
,LOD
NA
NA

NA
NA
0–4*
NA
NA

C

7
7

3.2
5.5

9.5
3.3

NA
7

NA
0.8

NA
0–4*

D

36
36

5.4
1.8

2
12

26c
NA

,LOD
NA

1
NA

E

6d
6
12
13
8

,LOD
,LOD
,LOD
4.6
1.5

7.3
13
12
1.3
6

6
NA
NA
NA
NA

,LOD
NA
NA
NA
NA

7
NA
NA
NA
NA

F

2
3
23

2.8
3.2
2.8

12
2
1

NA
NA
23

NA
NA
0.3

NA
NA
1

limit of detection (LOD) and limit of quantiﬁcation were, respectively, 0.1 and 0.2 m g/ml for CSF and 0.5 and 1.4 m g/ml for plasma. *, Between 0 and 4 h after BNZ
administration (the exact time was not recorded in the chart). CSF, cerebrospinal ﬂuid; NA, not available. Plasmatic and CSF BNZ concentrations are expressed as 60.1 m g/ml.
bCSF was obtained 1 day prior to the plasma sample.
cThe CSF sample was recovered 10 days prior to plasma sample.
dFor values in boldface, BNZ was administered using a nasogastric tube due to patient critical clinical status.
aThe

DISCUSSION
Management of HIV/AIDS patients with CNS involvement is very complex, requiring
the consideration of multiple, potentially overlapping and severe differential diagnoses
(e.g., neurotoxoplasmosis, lymphoma, neurotuberculosis, cryptococcosis, and others)
(17). Even though CD CNS reactivation is an infrequent opportunistic CNS infection in
HIV patients (17, 18), in areas of endemicity, such as Latin America, CD must be
included in the differential diagnosis of brain mass lesions or diffuse meningoencephalitis given its dire prognosis and potentially rapid progression. In this series, 4 of 6
patients died; in one of them, patient B, we could not obtain conﬁrmation of CD reactivation (i.e., brain biopsy was not possible), but CD was highly suspected, so empirical
BNZ treatment was given. All of the patients in this series were critical patients, and all
of them had extremely low CD4 counts and CNS compromise, so CD reactivation, as
well as any and all opportunistic diseases (including those conﬁrmed and those suspected that could not be ruled out), could be responsible for this high death rate.
As suggested in previous CD reactivation series in patients with HIV/AIDS, it is plausible that the difﬁculties in reaching a diagnosis of CD CNS reactivation, leading to
delays in implementing speciﬁc treatment (e.g., with BNZ), may be responsible for the
observed poor outcomes (1–4). Although, in this series, most patients started BNZ up
to day 2 of hospitalization, they still had a poor outcome. Alternative explanations for
this include the absence of pharmacokinetic and pharmacodynamic BNZ data in HIV
patients, making decisions on appropriate dosing, the duration of treatment, and evaluation of therapeutic responses an extremely difﬁcult and imprecise task.
Previously available BNZ CNS concentration data come from only two studies (19,
20). One study evaluated BNZ penetration into the CNS using CNS tumor biopsy specimens from 17 patients enrolled in a phase 2 clinical trial looking into BNZ treatment as
adjuvant chemotherapy. The tumor/mean plasma BNZ ratio was estimated to be .0.46
for all patients, meaning that BNZ CNS concentrations reached nearly 50% of those
observed in plasma (19). Another publication is a case report of a single immunocompromised renal transplanted patient with CD CNS reactivation in whom, due to poor
March 2021 Volume 65 Issue 3 e01922-20
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clinical CD CNS evolution, the BNZ dose was empirically doubled, and the BNZ levels in
CSF and plasma samples 3 h after dosing were 8.3 and 17.2 mg/liter, respectively (i.e., a
BNZ CSF/plasma ratio of 0.48) (20).
The only two survivors in our series had detectable BNZ in CSF, albeit at low levels,
and one of them was the only patient in our series for whom we were able to estimate
BNZ CSF/plasma ratios (i.e., 0.1), which was far below previously published CNS/plasma
or CSF/plasma ratios. These novel observations provoke two main questions: (i) why
the CSF BNZ measures in HIV/AIDS patients seemed lower than expected and (ii)
whether these low BNZ levels can still be effective, as suggested by these two surviving
patients. Unfortunately, we can only advance speculative answers to both of these
questions, in the hope that future clinical studies will conﬁrm (or reject) our hypothesis.
We believe that the low BNZ CNS levels can be explained by the fact that the timing of
the samples may have missed BNZ peak in CSF, suggesting a different PK in these
patients. Lumbar punctures in the survivors were done 1 and 7 h after the BNZ doses,
so the 1-h sampling time could have been before BNZ peak concentration, and the 7-h
sampling time could have captured the trough concentration in a patient with altered
PK (e.g., faster clearance, larger volume of distribution, and reduced absorption).
However, even if the CSF samples were not taken at the BNZ peak concentration, we
would have still expected higher CSF BNZ levels than observed. In the only patient for
whom we could calculate BNZ CSF/plasma ratio, that ratio was almost ﬁve times lower
than those reported in previous publications (19, 20). We believe that the low BNZ CNS
concentrations observed could also be due to reasons other than suboptimal sampling
timing, including a limited absorption of the drug from the gastrointestinal tract due to
the acute and severe clinical picture. Further potential explanations include drug-drug
interactions (e.g., all patients were on multiple medications, whose potential for interactions with BNZ have not been formally evaluated to date), and physiological alterations associated with the septic or clinical state of the patients, which could interfere with
BNZ CNS access due to altered BNZ pharmacokinetics. The second issue to take into consideration in the context of the survivors is that the BNZ parasite inhibitory concentration
may be lower than expected or that BNZ could act via a maximum concentration mechanism with extended postantiparasitic effects (similar to the postantibiotic effect of some
antibacterial drugs), affecting parasite growth even after BNZ levels decrease below the putative trypanocidal threshold. The efﬁcacy of lower concentrations of BNZ has been proposed by some preclinical and clinical assays (9, 10, 21, 22).
Patient E was the most critical patient in this series since he was under mechanical ventilation due to a depressed level of consciousness. Unfortunately, most of his samples
(plasma and CSF) had no measurable BNZ. We were really concerned about these new
data, so we looked into what may have interfered with BNZ. We initially inferred that the
reason for the undetectable BNZ could be due to the administration route, through nasogastric tube, since there is no intravenous BNZ available; however, patient F received BNZ
through a tube, too, and had normal plasma BNZ levels. The critical clinical condition of
patient E could have led to limited gastrointestinal absorption, modiﬁed drug volumes of
distribution, or the polypharmacy that could lead to drug interactions. In this setting, it is
not hard to envision that BNZ therapeutic drug monitoring could yield useful information
to better guide dosing decisions, especially in these patients.
The CD World Health Organization expert committee recommended, in 2002, BNZ
doses of 25 mg/kg/day for CD acute meningoencephalitis; however, this recommendation
was done empirically without published or personal communication data. These high
doses did not have any safety data either (23). To date, there is only one case report with
safety information on high BNZ doses (15 mg/kg/day) that were well tolerated (20).
Otherwise, studies on BNZ doses and schedules from 1979 showed greater and more frequent adverse events with doses between 7 and 10 mg/kg/day than with 5 mg/kg/day (7).
Consistent with previous data, we observed BNZ CNS concentrations that were signiﬁcantly
lower than those in plasma and also lower than previously observed (19, 20). This observation raises concerns of insufﬁcient BNZ exposure at current doses in T. cruzi CNS reactivation in HIV-positive patients. CD CNS reactivation patients may therefore require higher
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doses of trypanocidal drugs such as BNZ, or perhaps alternative treatment schedules that
may increase the CNS exposure and improve the likelihood of therapeutic response. If BNZ
dosing is increased in these patients, particularly given the risk of therapeutic failure, close
adverse event monitoring is advisable.
An important limitation of our study is that the samples were obtained for clinical (i.e.,
not pharmacokinetic) reasons, leading to quasirandom sampling times in regard to the
time of BNZ dose administration. However, as mentioned previously, BNZ pharmacokinetics data are scarce, and there are no accurate data available on its clearance, volume of
distribution, or penetration of the blood-brain barrier (with or without CNS inﬂammation)
in these patients. Therefore, we believe that the data presented here, albeit incomplete,
should help practitioners decide on BNZ dosing regimens, may establish BNZ measurement in critical patients during early follow-up, and should also prompt further BNZ clinical
pharmacology studies in this population, as well as encourage the pharmacological industry to develop an intravenous BNZ formulation.
Conclusion. Chagas disease reactivation in HIV patients is a severe complication frequently associated with fatal outcomes. Given the limited data on pharmacotherapy available in the literature, treatment decisions are guided by scarce data and often involve a signiﬁcant amount of guesswork. We believe that, in the face of such a dearth of evidence,
even limited case series, such as the one presented here, can be useful for clinicians dealing
with such difﬁcult cases.
Considering the importance of trypanocidal treatment in CD CNS reactivation, BNZ
bioavailability problems should be taken into account, and possibly BNZ measurement
in blood should be performed to conﬁrm therapeutic levels are needed for correct clinical treatment approach. It is also clear from our data that more in-depth knowledge on
BNZ pharmacology in these patients is urgently needed. Further clinical trials and
cohort studies should be encouraged to ﬁll this knowledge gap.
MATERIALS AND METHODS
A retrospective cohort study was carried out with six HIV- and T. cruzi-seropositive patients who presented with CNS involvement compatible with CD reactivation. Clinical charts of patients suspected for
CNS Chagas reactivation who received BNZ in our institution, the Hospital de Infecciosas FJ Muñiz,
Buenos Aires, Argentina, during a 4-year period (i.e., 2015 to 2019) were reviewed to identify patients eligible for this study. The study protocol was approved and informed consent was waived by the
Institutional Ethics in Research Committee of the Hospital de Infecciosas FJ Muñiz, Buenos Aires,
Argentina (DI-2020-98-GCABA-HIFJM).
Leftover CSF and plasma samples recovered at the Clinical Analysis Division of Hospital de Infecciosas FJ
Muñiz were retrieved for BNZ quantitation for all six patients. Clinical and laboratory information were
obtained from patient charts, including patient age, gender, origin, clinical signs and symptoms at presentation, and during hospital stay, HIV status (including CD4 lymphocyte counts, relevant microbiology studies,
concomitant medication, and clinical follow-up). CSF and plasma samples obtained during treatment were
recovered for all patients.
CSF and plasma samples were stored at 220°C until measurement by high-performance liquid chromatography/tandem spectrometry (HPLC-MS/MS) following a method developed by our group with the corresponding validation for its application in the CSF matrix (24). The method designed for BNZ plasma measurements was readapted and validated for CSF, as it is a different matrix sample. For validation procedures,
bovine CSF was used as a blank matrix to evaluate calibration curves and validation parameters. Plasma and
CSF calibration curves were prepared with known standards. Brieﬂy, after sample extraction, measurements
were carried out by HPLC-MS/MS (Shimadzu Nexera HPLC and Sciex QTrap 6500 mass spectrometer) using
MRM transition 261/91 in positive ESI mode for BNZ quantitation after chromatographic separation in a C18
HPLC column with isocratic methanol-water (65:35 [vol/vol]). Concomitant medications were chromatographically evaluated to ensure that they would not interfere with BNZ detection or quantitation in the analytical
method. The limit of detection (LOD) and limit of quantitation (LOQ) for BNZ were 0.1 and 0.2 m g/ml for CSF
samples and 0.5 and 1.4 m g/ml for plasma samples, respectively.
This study, including the use of stored leftover samples (originally obtained for clinical purposes),
was approved by the Institutional Ethics in Research Committee of the Hospital de Infecciosas FJ Muñiz,
Buenos Aires, Argentina (DI-2020-98-GCABA-HIFJM).
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